Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Guided Therapeutics, Inc. (GTHP) Trial Results To Be Featured In Upcoming Issue Of Gynecologic Oncology 0 comments
    May 2, 2013 2:33 PM

    Guided Therapeutics, a company developing an early detection testing platform based on its patented biophotonic technology, points to the publication of the clinical trial results of its LuViva® Advanced Cervical Scan in an upcoming issue of Gynecologic Oncology, the official publication of the Society of Gynecologic Oncology.

    The publication, authored by 10 doctors who conducted the trial, is entitled, "Multimodal hyperspectroscopy as a triage test for cervical neoplasia: Pivotal clinical trial results," demonstrating that LuViva detected 36.4 percent more cervical intraepithelial neoplasia (CIN2+) than tests used under current guidelines - creating the potential to significantly reduce unnecessary referrals of women with normal pathology.

    "Similar to other published studies, our study indicated that fewer than 20 percent of the women who are recalled after cervical screening actually have disease that requires treatment, resulting in a large number of women receiving unnecessary procedures, which creates an unnecessary burden on the financial and human resources of healthcare systems," Leo B. Twiggs, MD, lead author of the paper and Professor of Obstetrics and Gynecology at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, stated in the press release. "If used to triage women right after screening, LuViva could reduce those unnecessary procedures by 35 percent - 40 percent, thus significantly reducing health care expenditures in the field of cervical precancer and improving the patient's experience."

    Guided Therapeutics CEO Mark L. Faupel, Ph.D., further emphasized the significance of the positive results.

    "Results of the study demonstrate the value of LuViva to the patient, the physician, as well as the payer," he stated. "The patient benefits by receiving results immediately and avoiding unnecessary and painful follow-up procedures, the physician experiences enhanced practice efficiency and the payer reduces costs based on fewer unnecessary procedures."

    For more information guidedinc.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.